News

October 5, 2017

Alexo Therapeutics to Present ALX148 Clinical Data at the 32nd Annual Meeting of the Society for Immunotherapy of Cancer (SITC)  Read more   Download

April 10, 2017

Alexo Therapeutics Announces Initiation of Phase 1 Clinical Trial of ALX148 for the Treatment of Advanced Solid Tumors and Lymphoma  Read more   Download

July 25, 2016

BioCentury Emerging Company Profile of Alexo Therapeutics  Read article

Events

32nd Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

November 10, 2017, 12:30-2:00 pm ET – National Harbor, MD

Poster P241: A First-in-Human Study of ALX148: CD47 Blockade to Enhance Innate and Adaptive Immunity for Advanced Solid Tumor Malignancy and Non Hodgkin Lymphoma